SAN DIEGO, Jan. 3, 2017 /PRNewswire/ -- Neurocrine
Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine
Biosciences, will be presenting at the 35th Annual J.P.
Morgan Healthcare Conference in San
Francisco.
The live presentation takes place on Monday, January 9 at 2:30pm PT (5:30pm
ET). The presentation will be webcast and may be
accessed on the Company's website at
http://www.neurocrine.com.
Listeners are encouraged to visit the website approximately 5
minutes prior to the presentation to download or install any
necessary software. A replay of the presentation will be
available on the website approximately one hour after the
conclusion of the event and will be archived for one month.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc. discovers and develops innovative
and life-changing pharmaceuticals, in diseases with high unmet
medical needs, through its novel R&D platform, focused on
neurological and endocrine based diseases and disorders. The
Company's two lead late-stage clinical programs are elagolix, a
gonadotropin-releasing hormone antagonist for women's health that
is partnered with AbbVie Inc., and INGREZZA (valbenazine or
NBI-98854), a vesicular monoamine transporter 2 inhibitor for the
treatment of movement disorders. Neurocrine plans to commercialize
INGREZZA in the United States upon
approval by the FDA.
Neurocrine Biosciences, Inc. news releases are available through
the Company's website via the internet at
http://www.neurocrine.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-the-35th-annual-jp-morgan-healthcare-conference-300383511.html
SOURCE Neurocrine Biosciences, Inc.